ATC Abstracts

American Transplant Congress abstracts

  • Home
  • Meetings Archive
    • 2022 American Transplant Congress
    • 2021 American Transplant Congress
    • 2020 American Transplant Congress
    • 2019 American Transplant Congress
    • 2018 American Transplant Congress
    • 2017 American Transplant Congress
    • 2016 American Transplant Congress
    • 2015 American Transplant Congress
    • 2013 American Transplant Congress
  • Keyword Index
  • Resources
    • 2021 Resources
    • 2016 Resources
      • 2016 Welcome Letter
      • ATC 2016 Program Planning Committees
      • ASTS Council 2015-2016
      • AST Board of Directors 2015-2016
    • 2015 Resources
      • 2015 Welcome Letter
      • ATC 2015 Program Planning Committees
      • ASTS Council 2014-2015
      • AST Board of Directors 2014-2015
      • 2015 Conference Schedule
  • Search

Infections Following Rejection Therapies in Solid Organ Transplant Recipients

S. Gupta1, J. Gea-Banacloche2, H. Me3, D. M. Chascsa4, H. R. Vikram2, R. Yaman1, L. Kodali3

1Internal Medicine, Mayo Clinic, Scottsdale, AZ, 2Infectious Diseases, Mayo Clinic, Phoenix, AZ, 3Transplant Nephrology, Mayo Clinic, Phoenix, AZ, 4Hepatology, Mayo Clinic, Phoenix, AZ

Meeting: 2022 American Transplant Congress

Abstract number: 693

Keywords: Graft failure, Infection, Kidney/liver transplantation, Rejection

Topic: Clinical Science » Infection Disease » 24 - All Infections (Excluding Kidney & Viral Hepatitis)

Session Information

Session Name: All Infections (Excluding Kidney & Viral Hepatitis) I

Session Type: Poster Abstract

Date: Saturday, June 4, 2022

Session Time: 5:30pm-7:00pm

 Presentation Time: 5:30pm-7:00pm

Location: Hynes Halls C & D

*Purpose: Infections are known complications of solid-organ transplant. They are most prevalent in the first 12 months after transplant when immunosuppression is at its peak. There is a lack of research regarding infections that occur after treatment of transplant rejection. We aim to study patients treated for rejection and understand the differences between those who did and did not develop infections, and thereby understand risk factors for infections.

*Methods: We conducted a retrospective chart review of all liver and kidney transplant recipients treated for rejection at our institution from 2014 to 2020. Only episodes of rejection within 1 year of transplant and infections within 6 months of rejection treatment were included.

*Results: We identified 257 (199 kidney, 50 liver, 8 simultaneous liver kidney) transplant patients treated for rejection. 112 (43.6%) developed infections and 145 did not. Most common infections are in Table 1. Female gender was found to be a predictor of infection development (p=0.01) (Table 2,3). Eculizumab and plasmapheresis for treatment of rejection were found to be predictors of infections (p=0.04 and 0.05) (Table 4). Outcome data of death at any point and graft loss within 6 months of infection were analyzed and graft loss was found to be significantly associated with infections (p=0.01). Figures 1 and 2 show the association of time to death and graft loss with infections. Though there was no significant difference in patient survival in 2 groups, both allografts had increased failure rates in association with infections.

*Conclusions: Female gender and administration of eculizumab and plasmapheresis for rejection treatment were found to be risk factors for infection. Infections were predictors of graft loss. Though time to death after kidney transplant by infection status was not significant, its p-value indicates that infections may identify a group of patients who are more likely to experience poor outcomes. Further analysis of our data will elucidate relationships between predictors of infection and their associated specific infections.

  • Tweet
  • Email
  • Print

To cite this abstract in AMA style:

Gupta S, Gea-Banacloche J, Me H, Chascsa DM, Vikram HR, Yaman R, Kodali L. Infections Following Rejection Therapies in Solid Organ Transplant Recipients [abstract]. Am J Transplant. 2022; 22 (suppl 3). https://atcmeetingabstracts.com/abstract/infections-following-rejection-therapies-in-solid-organ-transplant-recipients/. Accessed May 9, 2025.

« Back to 2022 American Transplant Congress

Visit Our Partner Sites

American Transplant Congress (ATC)

Visit the official site for the American Transplant Congress »

American Journal of Transplantation

The official publication for the American Society of Transplantation (AST) and the American Society of Transplant Surgeons (ASTS) »

American Society of Transplantation (AST)

An organization of more than 3000 professionals dedicated to advancing the field of transplantation. »

American Society of Transplant Surgeons (ASTS)

The society represents approximately 1,800 professionals dedicated to excellence in transplantation surgery. »

Copyright © 2013-2025 by American Society of Transplantation and the American Society of Transplant Surgeons. All rights reserved.

Privacy Policy | Terms of Use | Cookie Preferences